Search - tctmd.com

Displaying 41 - 54 of 54

Sort: Relevancy | Date

News Conference News ACC 2019

Apple Watch May Detect A-fib in the General Population, but at What Cost?

Yael L. Maxwell

March 16, 2019

News Conference News ACC 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Michael O'Riordan

March 01, 2018

News Conference News ACC 2017

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

Michael O'Riordan

March 24, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2016

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

Shelley Wood

April 08, 2016

News Conference News ACC 2016

Older Men With Existing Coronary Disease at Highest Risk of Dying During a Triathlon

Michael O'Riordan

April 06, 2016

News Conference News ACC 2016

‘Enhanced’ Multicellular Stem Cell Therapy Improves Clinical Outcomes in Heart Failure: ixCELL-DCM Study

Michael O'Riordan

April 04, 2016

News Conference News ACC 2016

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

Caitlin E. Cox

April 02, 2016

News Conference News ACC 2014

Intramyocardial Injection of Stem Cells Shows Promise for Severe Ischemic Heart Failure

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2014

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Yael L. Maxwell

March 29, 2014

News Conference News

TEST - COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

Shelley Wood

April 10, 2001

Video

» Interview

Updated Cumulative Results of Treatment with Mavacamten from the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients with Obstructive Hypertrophic Cardiomyopathy

May 4, 2022

Video

» Interview

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

May 4, 2022

Video

» Interview

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

April 3, 2022

Advertisement

Apple Watch May Detect A-fib in the General Population, but at What Cost?

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

Live From Washington: ACC 2017, Day One

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

Older Men With Existing Coronary Disease at Highest Risk of Dying During a Triathlon

‘Enhanced’ Multicellular Stem Cell Therapy Improves Clinical Outcomes in Heart Failure: ixCELL-DCM Study

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

Intramyocardial Injection of Stem Cells Shows Promise for Severe Ischemic Heart Failure

TAVR With the CoreValve Device Superior to Surgery at 1 Year

TEST - COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

Updated Cumulative Results of Treatment with Mavacamten from the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients with Obstructive Hypertrophic Cardiomyopathy

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content